Mangalam Drugs and Organics Share Price

28.180.27 (0.97%)

Closed
As On: 12 Jun, 2026, 03:41 PM IST
As On: 12 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	28.79
High	29.00
Low	27.76
Prev Close	27.91
Volume	19,296
VWAP(₹)	28.02

Share Price	Value
Today/Current/Last	28.1828.46
Previous Day	27.9128.00

Mangalam Drugs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Mangalam Drugs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	67.38	58.60	49.57	57.35	73.25
Total Income Growth (%)	14.98	18.21	-13.56	-21.71	-17.56
Total Expenses	77.57	64.38	62.04	66.30	67.58
Total Expenses Growth (%)	20.48	3.77	-6.43	-1.90	-19.54
EBIT	-10.19	-5.78	-12.47	-8.95	5.66
EBIT Growth (%)	-	-	-	-258.06	16.67
Profit after Tax (PAT)	-13.42	-9.84	-7.35	-13.80	0.06
PAT Growth (%)	-	-	-	0.00	-95.38
EBIT Margin (%)	-15.12	-9.87	-25.15	-15.61	7.73
Net Profit Margin (%)	-19.92	-16.78	-14.82	-24.06	0.08
Basic EPS (₹)	-8.48	-6.21	-4.64	-8.72	0.04

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	67.38	58.60	49.57	57.35	73.25
Total Income Growth (%)	14.98	18.21	-13.56	-21.71	-17.55
Total Expenses	77.21	64.32	56.91	66.23	67.49
Total Expenses Growth (%)	20.03	13.03	-14.07	-1.87	-19.53
EBIT	-9.83	-5.73	-7.34	-8.88	5.76
EBIT Growth (%)	-	-	-	-254.33	15.79
Profit after Tax (PAT)	-13.06	-9.78	-7.25	-13.73	0.15
PAT Growth (%)	-	-	-	0.00	-89.24
EBIT Margin (%)	-14.59	-9.77	-14.80	-15.49	7.86
Net Profit Margin (%)	-19.38	-16.69	-14.62	-23.94	0.21
Basic EPS (₹)	-8.25	-6.18	-4.58	-8.67	0.10

	FY 2026	FY 2025
Total Revenue	232.90	318.73
Total Revenue Growth (%)	-26.93	-13.55
Total Expenses	281.47	313.95
Total Expenses Growth (%)	-10.35	-17.33
Profit after Tax (PAT)	-44.40	6.72
PAT Growth (%)	-760.65	-
Operating Profit Margin (%)	-13.94	6.19
Net Profit Margin (%)	-19.12	2.11
Basic EPS (₹)	-28.05	4.25

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	232.90	318.73	368.69	372.69	451.16
Total Revenue Growth (%)	-26.93	-13.55	-1.07	-17.39	17.23
Total Expenses	280.88	313.74	379.75	370.47	423.42
Total Expenses Growth (%)	-10.47	-17.38	2.50	-12.51	22.61
Profit after Tax (PAT)	-43.81	6.92	-9.05	1.27	19.66
PAT Growth (%)	-732.76	-	-812.51	-93.54	-29.72
Operating Profit Margin (%)	-13.69	6.26	0.77	4.02	8.62
Net Profit Margin (%)	-18.87	2.17	-2.45	0.34	4.35
Basic EPS (₹)	-27.68	4.37	-5.72	0.80	12.42

All figures in Rs Cr, unless mentioned otherwise

Insights

PAT: Troublesome Times
Company has posted a loss of Rs 13.42 cr for the 4th consecutive quarter. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 6.98% of its operating revenues towards interest expenses and 14.56% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025
Total Assets	314.97	366.42
Total Assets Growth (%)	-14.04	9.81
Total Liabilities	211.91	217.44
Total Liabilities Growth (%)	-2.54	9.87
Total Equity	103.06	148.98
Total Equity Growth (%)	-30.82	9.71
Current Ratio (x)	0.79	1.04
Total Debt to Equity (x)	1.02	0.54
Contingent Liabilities	0.00	34.64

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	308.14	359.24	357.14	359.63	328.43
Total Assets Growth (%)	-14.22	0.59	-0.69	9.50	24.95
Total Liabilities	204.82	210.58	214.80	207.67	177.86
Total Liabilities Growth (%)	-2.74	-1.96	3.43	16.76	34.85
Total Equity	103.32	148.66	142.35	151.96	150.56
Total Equity Growth (%)	-30.50	4.43	-6.32	0.93	14.97
Current Ratio (x)	0.82	1.08	1.10	1.25	1.40
Total Debt to Equity (x)	0.99	0.55	0.62	0.45	0.48
Contingent Liabilities	0.00	34.64	11.96	26.33	6.26

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025
Net Cash flow from Operating Activities	4.18	42.59
Net Cash used in Investing Activities	-11.72	-19.47
Net Cash flow from Financing Activities	5.66	-21.71
Net Cash Flow	-1.89	1.41
Closing Cash & Cash Equivalent	0.70	2.59
Closing Cash & Cash Equivalent Growth (%)	-72.92	119.47
Total Debt/ CFO (x)	25.25	1.91

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	4.16	42.76	12.17	39.52	25.71
Net Cash used in Investing Activities	-11.72	-19.47	-17.91	-22.17	-27.33
Net Cash flow from Financing Activities	5.66	-21.71	5.70	-16.62	2.98
Net Cash Flow	-1.90	1.57	-0.04	0.73	1.36
Closing Cash & Cash Equivalent	0.67	2.57	1.00	2.68	1.95
Closing Cash & Cash Equivalent Growth (%)	-73.87	157.59	-62.73	37.69	228.98
Total Debt/ CFO (x)	24.51	1.90	7.23	1.73	2.81

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 11.72 cr for investing activities which is an YoY decrease of 39.79%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025
Return on Equity (%)	-43.08	4.51
Return on Capital Employed (%)	-27.33	11.27
Return on Assets (%)	-14.09	1.83
Interest Coverage Ratio (x)	-0.87	2.43
Asset Turnover Ratio (x)	0.68	0.91
Price to Earnings (x)	-0.99	17.48
Price to Book (x)	0.43	0.79
EV/EBITDA (x)	-10.52	5.40
EBITDA Margin (%)	-6.09	11.41

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-42.40	4.65	-6.35	0.83	13.05
Return on Capital Employed (%)	-26.78	11.41	1.62	7.70	19.61
Return on Assets (%)	-14.21	1.92	-2.53	0.35	5.98
Interest Coverage Ratio (x)	-0.86	2.43	1.26	2.04	4.40
Asset Turnover Ratio (x)	0.70	0.89	1.03	1.08	1.53
Price to Earnings (x)	-1.00	16.98	-16.23	123.46	8.29
Price to Book (x)	0.42	0.79	1.03	1.02	1.08
EV/EBITDA (x)	-10.43	5.40	13.35	8.50	4.74
EBITDA Margin (%)	-6.00	11.40	4.74	6.97	10.89

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Mangalam Drugs	-1.00	0.43	-43.08	-27.33	-14.09	-14.37	-13.94	-19.12	-28.05	0.79	1.02	25.25
Aarey Drugs	48.81	1.47	2.63	6.84	1.33	4.25	2.20	0.84	1.39	1.81	0.33	4.93
Natural Capsule	-7.00	0.69	-7.70	-5.82	-4.02	2.96	-9.06	-13.17	-23.84	1.03	0.52	10.47
Alpa Labs	10.27	0.79	7.58	8.94	5.83	5.85	16.02	13.35	6.71	4.01	0.01	0.24
Krebs Biochem	-8.31	-0.86	0.00	-19.62	-10.37	-21.07	-41.49	-71.35	-7.85	0.09	-1.38	-117.07
Add More

Annual Ratios (%)

Choose from Peers

Bal Pharma
Par Drugs & Chemical
Vaishali Pharma
Biofil Chem
Ortin Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Mangalam Drugs Stock Performance	0.97	-7.76	-1.88	-10.99	-64.15	-73.83	-79.33
Aarey Drugs Stock Performance	2.30	-14.73	-11.70	-0.85	46.14	178.04	0.00
Natural Capsule Stock Performance	1.57	0.07	-2.93	-1.30	-21.57	0.00	0.00
Alpa Labs Stock Performance	3.90	2.18	1.31	4.15	-34.88	18.52	23.35
Krebs Biochem Stock Performance	2.76	15.33	6.07	11.31	-12.33	0.59	-49.45
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	56,43,030	35.65 %	0.00
Pledge	0	0.00 %	-7.09
FII	51,011	0.31 %	0.18
DII	0	0.00 %	0.00
MF	0	0.00 %	0.00
Others	1,01,34,207	64.03 %	-0.18

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	35.65	35.64	50.30	50.30
Pledge	0.00	7.09	34.58	13.23
FII	0.31	0.13	0.11	0.53
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	64.03	64.22	49.59	49.17

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
General Meeting
-
May 18, 2026
Board Meeting
Audited Results
May 06, 2026
Board Meeting
Others
Mar 24, 2026

Board Meetings

Announced on	Meeting on
May 06, 2026	May 14, 2026
Audited Results
Mar 24, 2026	Mar 26, 2026
Others
Feb 04, 2026	Feb 06, 2026
Others
Jan 07, 2026	Jan 15, 2026
Quarterly Results
Nov 13, 2025	Nov 20, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
Dec 12, 2017 Dec 21, 2017 5%
Jul 04, 2006 Sep 19, 2006 2%
Jun 13, 2005 Aug 30, 2005 2%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
May 18, 2026 Jun 19, 2026
-
Sep 09, 2025 Sep 29, 2025
-
Jul 14, 2025 Aug 12, 2025
-
Aug 13, 2024 Sep 26, 2024
-
Aug 10, 2023 Sep 29, 2023
-

Announced on	Ex-Date	Dividend%
Dec 12, 2017	Dec 21, 2017	5%
Jul 04, 2006	Sep 19, 2006	2%
Jun 13, 2005	Aug 30, 2005	2%

Announced on	Meeting on
May 18, 2026	Jun 19, 2026
-
Sep 09, 2025	Sep 29, 2025
-
Jul 14, 2025	Aug 12, 2025
-
Aug 13, 2024	Sep 26, 2024
-
Aug 10, 2023	Sep 29, 2023
-

About Mangalam Drugs

Mangalam Drugs and Organics Ltd., incorporated in the year 1972, is a Small Cap company (having a market cap of Rs 44.60 Crore) operating in Pharmaceuticals sector.

Mangalam Drugs and Organics Ltd. key Products/Revenue Segments include Pharmaceuticals, Traded Goods, Service Charges, Other Services, Other Operating Revenue and Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 67.38 Crore, up 14.98 % from last quarter Total Income of Rs 58.60 Crore and down 8.02 % from last year same quarter Total Income of Rs 73.25 Crore. Company has reported net profit after tax of Rs -13.42 Crore in latest quarter.

The company’s top management includes Mr.Govardhan Murlidhar Dhoot, Mr.Brijmohan Murlidhar Dhoot, Mr.Rakesh Kishinchand Milwani, Mrs.Nidhi Shantanu Mundada, Mr.Praveen Saxena, Mr.Rukmesh Prabhukumar Dhandhania, Mr.Ajay Avinash Samant, Ms.Anuradha Pandey. Company has Batliboi & Purohit as its auditors. As on 31-03-2026, the company has a total of 1.58 Crore shares outstanding.

Mangalam Drugs Share Price Today is Rs. 28.18. On previous day, the Mangalam Drugs Share Price (NSE) closed at Rs. 27.91, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 35.65% of the stake in Mangalam Drugs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Mangalam Drugs stocks was 0.32% as compared to 0.13% in Dec 2025 with increase of 0.19%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Mangalam Drugs shares 0.0% was held by mutual funds. The rest including public held is 64.03%. Mangalam Drugs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Mangalam Drugs Dividend: Ever since 1972, Mangalam Drugs dividends has been paid out around 3 times. As on 12 Jun, 2026, 03:41 PM IST, The overall dividend yield for Mangalam Drugs stands at 0.0%. The last dividend paid was on December 21, 2017 (Rs. 0.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. -28.05.

Mangalam Drugs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 67.38 Cr. of sales and 14.76% of quarterly net profit, there have been multiple ups and downs in the Mangalam Drugs stock prices in the past few weeks. For example, Mangalam Drugs stock price on 5th of June 2026 was around Rs. 28.5. Mangalam Drugs share price now stands at an average of Rs. 28.18. Judging by last week's performance, stock is in down trend.

Mangalam Drugs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Mangalam Drugs share.

Historical Prices and Performance:
Mangalam Drugs, incorporated in 1972 is a Small Cap company (with a market cap of Rs. 44.6) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Mangalam Drugs stock was -43.08%, 4.51%, -6.68%, 0.83% and 13.05% respectively.
The Mangalam Drugs share gave a 3 year return of -73.03% as compared to Nifty 50 which gave a return of 26.99%.
Mangalam Drugs announced 5.0% final dividend on December 21, 2017.

Key Metrics:
PE Ratio of Mangalam Drugs is -1.0
Prices/Sales Ratio of Mangalam Drugs is 0.19
Price/Book Ratio of Mangalam Drugs is 0.43

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Mangalam Drugs, major competitors and peers include Aarey Drugs, Natural Capsule, Alpa Labs and Krebs Biochem. As of Dec 2025, the dividend yield of Mangalam Drugs stands at 0.0% while Aarey Drugs, Natural Capsule, Alpa Labs and Krebs Biochem stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at -1.0 and 0.43 respectively.

Leadership of Mangalam Drugs :
Anuradha Pandey is Co. Secretary & Compl. Officer
Ajay Avinash Samant is Chief Financial Officer
Govardhan Murlidhar Dhoot is Chairman & Managing Director
Brijmohan Murlidhar Dhoot is Whole Time Director
Praveen Saxena is Independent Director
Rakesh Kishinchand Milwani is Non Exe.Non Ind.Director
Rukmesh Prabhukumar Dhandhania is Independent Director
Nidhi Shantanu Mundada is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Rupam Building, 3rd Floor,239, P.D. Mello Road,Mumbai, Maharashtra - 400001

Contact

contactus@mangalamdrugs.com

http://www.mangalamdrugs.com

PE Ratio(x)	-1.00
EPS - TTM(₹)	-28.05
MCap(₹ Cr.)	44.60
MCap Rank	117
PB Ratio(x)	0.43
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	95.00
52W Low(₹)	22.80
MCap/Sales	0.19
Beta(1 Month)	1.34
BV/Share(₹)	65.11

PE Ratio(x)	-1.01
EPS - TTM(₹)	-28.05
MCap(₹ Cr.)	45.05
MCap Rank	155
PB Ratio(x)	0.43
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	94.80
52W Low(₹)	22.70
MCap/Sales	0.19
Beta(1 Month)	1.77
BV/Share(₹)	65.11

1 Day	0.97%
1 Month	-9.68%
3 Months	-11.72%
1 Year	-65.7%
3 Years	-73.03%
5 Years	-78.49%

1 Day	1.64%
1 Month	-7.45%
3 Months	-12.43%
1 Year	-65.39%
3 Years	-72.83%
5 Years	-78.29%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Mangalam Drugs and Organics Share Price

Key Metrics

Mangalam Drugs share price insights

Mangalam Drugs Share Price Returns

Mangalam Drugs Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Mangalam Drugs Top Searches

Corporate Actions

About Mangalam Drugs

Executive Leadership

Auditors

FAQs about Mangalam Drugs share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News